Jung et al. (141) has shown that VC could enhance anti-EGFR efficacy of cetuximab by increasing ROS production in KRAS mutant colon cancer cell xenografts in a manner that was dependent on the expression levels of the SVCT2. Here, KRAS is linked to malignant colon neoplasm.